Conference
1748P 4-factor model to predict response and survival benefit with durvalumab (D) in previously treated metastatic urinary tract carcinoma (mUTC)
Authors
Sonpavde GP; Sternberg CN; Lee J-L; Emeribe U; Oh SM; De Lima ARD; Hotte SJ
Volume
33
Publisher
Elsevier
Publication Date
September 1, 2022
DOI
10.1016/j.annonc.2022.07.1826
Conference proceedings
Annals of Oncology
ISSN
0923-7534